- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04928222
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
April 11, 2023 updated by: SkinJect, Inc.
A Trial to Evaluate Placebo Microneedle Arrays in Healthy Human Volunteers (Part I), Followed by Proof of Concept Testing of Efficacy and Safety of Doxorubicin Microneedle Arrays in Subjects With Basal Cell Cancer (Part II)
Part I is designed as a study of P-MNA application in healthy human volunteers.
The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic location; age; duration of array exposure to the skin; and the criticality of proper array application to the skin.
Part II will be a randomized study in which doxorubicin-containing arrays will be applied to subjects demonstrated by biopsy to have basal cell cancer.
A subject will be randomized to one of four dose groups: placebo microneedle array and 50 µg, 100 µg, and 200 µg doses of doxorubicin in a tip-loaded, dissolvable microneedle arrays (D-MNA).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael J Fare
- Phone Number: 2035332050
- Email: mfare@skinjectpatch.com
Study Contact Backup
- Name: Susan M Buttler
- Email: sbuttler@skinjectpatch.com
Study Locations
-
-
Florida
-
West Palm Beach, Florida, United States, 33411
- Beer Dermatology
-
-
New York
-
New York, New York, United States, 10032
- New York and Presbyterian Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adult males and females, 18+ years in general good health as assessed by the investigator.
Clinical laboratory results within the following ranges:
- granulocytes ≥2,000/mm3
- platelets >50,000/mm3
- serum creatinine ≤2X the upper limit of normal (ULN)
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), alkaline phosphatase ≤3X the ULN.
- Subject must have no other "clinically significant" abnormal findings in his/her medical history, physical examination or clinical laboratory test results as assessed by the investigator.
- Subject must be willing to adhere to the instructions of the investigator and his or her research team.
- Subject must sign an Informed Consent Form prior to any study specific procedures and entry into the study.
- BCC (subtype: superficial or nodular) confirmed histologically by diagnostic shave biopsy at the Screening Visit. If previously confirmed, subjects can only have diagnosed BCC via shaved biopsy within 6 months of first study treatment.
- Biopsy removed ≤25% of the original volume of the target lesion.
- Primary BCC (i.e., no previous treatment)
- Lesion size ≥ 64 mm2 or 8 x 8 mm and ≤ 169 mm2 or 13 x 13 mm, i.e., the entire lesion must be covered by 13X13 mm area of the array containing the microneedles
- Subjects must avoid sunlight/ultraviolet light to the target lesion for the duration of the study.
Female subjects must be:
- postmenopausal (no menstrual period for a minimum of 12 months), or
- surgically sterile upon entry into the study.
- female subjects of childbearing potential must have a negative pregnancy test upon entry into this study and agree to use a highly effective method of contraception from Screening until the final follow-up visit. Consult Section 5.5 in this protocol for a description of effective contraceptive methods. Female subjects must also have negative pregnancy tests before each dose is applied to female subjects
- Male subjects with female partners of child bearing potential must be either surgically sterile or agree to use a double-barrier contraception method (i.e., condom + diaphragm, condom or diaphragm + spermicidal gel or foam) from screening until the final follow-up visit.
Exclusion Criteria:
- Evidence of clinically significant, unstable medical conditions as assessed by the investigator.
- Previously demonstrated sensitivity to doxorubicin or carboxymethyl cellulose.
- Female subjects who are pregnant or breastfeeding.
- The subject has uncontrolled, significant intercurrent or recent illness.
- Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g. dabigatran), betrixaban, or platelet inhibitors (eg, clopidogrel). Prophylactic use of Low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH) are permitted.
- Topical therapy(ies) to the target lesion within 6 weeks of first treatment.
- Prior excisional surgery performed on the lesion to be treated in this study.
- Recent therapy(ies) to the BCC treatment area.
- Recurrent BCC (previously treated) at the site presented for treatment.
- BCC lesion to be treated is located in an area where excisional biopsy is undesired or aesthetically unacceptable to the subject
- Subject with other active malignancies except for non-metastatic prostate cancer, carcinoma in situ of the skin or cervix, and basal cell cancer in locations other than lesion of interest.
- Subject with evidence of metastatic malignancies.
- Concomitant disease requiring systemic immunosuppressive treatment.
- Genetic skin cancer disorder, e.g., basal cell nevus syndrome.
- Subject is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment (patients who are in a follow-up phase of an investigational study may participate as long as it has been 30 days after the last dose of the previous investigational agent).
- Evidence of dermatological disease or confounding skin condition within 3 mm margin of the target BCC lesion, e.g., SCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema.
- Existing condition or treatment within 3 months prior to the Screening Visit that may have impact on clinical outcome for the treatment of BCC or delay in wound healing from the standard of care excision.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Doxorubicin-containing MNA - 100 µg
A doxorubicin-containing array of 100 µg will be applied to subjects.
|
A 15 x 15 millimeter array containing 400 dissolvable microneedles delivering active agent
|
Experimental: Placebo MNA for Training
Training phase for application of arrays
|
A 15 15 x 15 millimeter array containing 400 dissolvable microneedles containing placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with Eradication of Basal Cell Cancer based on Histologic Analysis
Time Frame: Up to 4 weeks after the last array application to a subject
|
Tissue will be excised and sectioned for histologic analysis
|
Up to 4 weeks after the last array application to a subject
|
Number of subjects with dose-limiting toxicity and treatment-related adverse events by CTCAE v4.0
Time Frame: Assessment at week 2 of subject visit
|
Determination of cutaneous tolerability of arrays after application
|
Assessment at week 2 of subject visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Susan M Buttler, SkinJect, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 24, 2021
Primary Completion (Anticipated)
December 30, 2023
Study Completion (Anticipated)
June 30, 2024
Study Registration Dates
First Submitted
June 3, 2021
First Submitted That Met QC Criteria
June 15, 2021
First Posted (Actual)
June 16, 2021
Study Record Updates
Last Update Posted (Actual)
April 14, 2023
Last Update Submitted That Met QC Criteria
April 11, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Carcinoma, Basal Cell
- Neoplasms, Basal Cell
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
Other Study ID Numbers
- SKNJCT-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Graceway Pharmaceuticals, LLCCompletedSuperficial Basal Cell CarcinomaAustralia, New Zealand
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Biofrontera Bioscience GmbHActive, not recruitingSuperficial Basal Cell CarcinomaUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Catharina Ziekenhuis EindhovenCompletedSuperficial Basal Cell CarcinomaNetherlands
-
Maastricht University Medical CenterActive, not recruitingNodular Basal Cell CarcinomaNetherlands
Clinical Trials on Placebo-containing MNA
-
SkinJect, Inc.Terminated
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre and other collaboratorsCompletedHypertriglyceridemiaCanada
-
University GhentUniversity Hospital, Ghent; Universitair Ziekenhuis Brussel; Vrije Universiteit... and other collaboratorsCompletedChronic Low Back Pain | Chronic Neck Pain | Insomnia ChronicBelgium
-
Michal ChudzikCompletedCovid19 | Fatigue Syndrome, ChronicPoland
-
Pharmena North AmericaCompletedHyperlipidemiaUnited States
-
Prince of Songkla UniversityRecruitingCardiac Surgery | Postoperative Pulmonary Complication | Elderly Patient | Nutrition Scoring SystemThailand
-
Cortria CorporationCompleted
-
Cortria CorporationCompletedHyperlipidemia
-
University of BariCompletedIrritable Bowel Syndrome | Non-celiac Gluten SensitivityItaly
-
Amazentis SAGoethe UniversityActive, not recruiting